- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
- Interventions
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Serdexmethylphenidate/dexmethylphenidate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ADHD, ADD
- Interventions
- Dexmethylphenidate HCl extended-release capsules
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 252 participants
- Timeline
- 2006
- U.S. locations
- 25
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
- Conditions
- ADHD
- Interventions
- KP415 oral capsule
- Drug
- Lead sponsor
- Zevra Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Colorado Springs, Colorado • Bradenton, Florida + 15 more
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Drug
- Lead sponsor
- Corium, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
- Conditions
- ADHD
- Interventions
- Focalin XR
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- Dexmethylphenidate Hydrochloride
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- ADHD
- Interventions
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas